Host Immune Response to Infection and Cancer: Unexpected Commonalities  by Goldszmid, Romina S. et al.
Cell Host & Microbe
ReviewHost Immune Response to Infection and Cancer:
Unexpected CommonalitiesRomina S. Goldszmid,1 Amiran Dzutsev,1,2 and Giorgio Trinchieri1,*
1Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
2Leidos Biomedical Research, Inc., Frederick, MD 21701, USA
*Correspondence: trinchig@mail.nih.gov
http://dx.doi.org/10.1016/j.chom.2014.02.003
Both microbes and tumors activate innate resistance, tissue repair, and adaptive immunity. Unlike acute
infection, tumor growth is initially unapparent; however, inflammation and immunity affect all phases of tumor
growth from initiation to progression and dissemination. Here, we discuss the shared features involved in the
immune response to infection and cancer including modulation by commensal microbiota, reactive hemato-
poiesis, chronic immune responses and regulatory mechanisms to prevent collateral tissue damage. This
comparative analysis of immunity to infection and cancer furthers our understanding of the basic mecha-
nisms underlying innate resistance and adaptive immunity and their translational application to the design
of new therapeutic approaches.Introduction
Organisms resist infections by establishing barriers and acti-
vating different classes of innate resistance and adaptive immu-
nity. The tissue in which the infection occurs regulates the
strength, quality, and type of the immune response for efficient
pathogen eradication and tissue repair while limiting collateral
tissue damage (Matzinger and Kamala, 2011). However, some
microbes have evolved evasion mechanisms that thwart these
host responses, resulting in uncontrolled or chronic infection
associated with pathologic damage.
Unlike the traditional view of immunity as a response to foreign
microbes and molecules, the primary trigger for innate resis-
tance, which is followed by adaptive immunity in higher organ-
isms, may be the sensing of altered self, such as changes in
tissue homeostasis or integrity (Matzinger, 2002; Medzhitov,
2008). Innate receptors respond to microbe-associated molecu-
lar patterns (MAMPs) and also endogenous mediators of in-
flammation released by damaged tissues (damage-associated
molecular patterns [DAMPs]). These tissue-intrinsic inflamma-
tory responses are amplified by the recruitment of hematopoietic
cells that express innate receptors for exogenous and endoge-
nous ligands present in the inflamed tissue and set the stage,
via antigen presentation and activation of T and B cells, for adap-
tive immunity.
Tumors may originate at sites of chronic inflammation that are
either caused by infectious pathogens or often aseptic. Never-
theless, tumors eventually establish an almost symbiotic rela-
tionship with their host that mimics chronic infections or
cohabitation with commensal microorganisms and maintain
their presence by suppressing excessive inflammation and anti-
tumor immune responses. The molecular alterations in the trans-
formed cells or the surrounding epithelial and stromal cells are
associated with a proinflammatory wound-healing microenvi-
ronment that, in addition to providing tumor growth and angio-
genic factors, affects tissue remodeling and decreases the
expression of molecules involved in cell-to-cell adhesion, initi-
ating the epithelial-mesenchimal progression, which can lead
to tumor cell invasion and progression (Edme et al., 2002; Sal-cedo et al., 2013). Nucleic acids and other products released
upon cell stress or death in more advanced tumors or, following
cytotoxic therapy, are recognized by innate sensors, resulting in
the inflammation and activation of antigen-presenting cells
(APCs) (Ma et al., 2013b). Thus, like infection, tumors influence
and are affected by inflammation and immunity from their early
initiation to progression, dissemination, and eventually death of
the host. Cancer-associated inflammation not only affects local
tumor growth and dissemination but is also responsible for
severe cancer-associated comorbidities, such as anorexia,
cachexia, and immunosuppression, making cancer a systemic,
rather than localized, disease (Trinchieri, 2012). Malignant
growth originates within differentiated tissues and maintains
some of the functional, morphologic, and immune traits of the tis-
sue of origin, representing a ‘‘caricature’’ of the original tissue
(Pierce and Speers, 1988). The immune response elicited by
the tumor will be, in most cases, unable to eradicate it and will
establish a Darwinian environment that selects the genetically
fittest cancer cells (tumor editing and escape) that evolve into
aggressive malignant tumors or, in some cases, remain tempo-
rarily in equilibrium with nonmalignant host cells (Schreiber
et al., 2011).
Given the parallels between immunity to infection and cancer,
this review focuses on the similarities and differences in these
processes and how these two fields can help each other in
advancing our understanding of innate resistance and immunity.
Inflammation and Cancer
Inflammation and immunity are inherent characteristics of can-
cer, and avoiding immune destruction and tumor-promoting
inflammation are now among the hallmarks of cancer (Hanahan
and Weinberg, 2011). Up to a quarter of human cancers are
related to infection or infection-associated chronic inflammation.
Helicobacter pylori, human papillomaviruses (HPVs), Epstein-
Barr virus (EBV), and hepatitis B and C viruses are the most
common etiopathogenic factors (Parkin, 2006). Some oncogenic
pathogens directly transform the tumor-forming cells (e.g.,
EBV or HPV), whereas others (e.g., H. pylori) establish anCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 295
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initiate in tissues chronically inflamed for causes other than infec-
tion; e.g., tissue injury by physical or chemical insults or genetic
diseases. Altered composition (dysbiosis) of the intestinal micro-
biota or its physical interaction with hematopoietic cells also
regulate inflammation and has been shown to be a cause of
cancer (Goldszmid and Trinchieri, 2012; Jobin, 2012; Rao
et al., 2006). The class of inflammatory and immune response
observed in tumors is determined by the characteristics of the
originating tissue, the proinflammatory mediators released by
the tumor cells or their stroma, and the nature of tissue damage,
pathogens, or commensals associated with carcinogenesis.
Although most proinflammatory cytokines may have pleiotropic
pro- or antitumor effects, the classes of immune response with
a predominant role in tissue repair and angiogenesis (e.g., the
Th-2 response or the alternatively activated M2 macrophages)
are most likely tumor promoting, whereas tissue and tumor
damaging responses (e.g., Th1 or classically activated M1 mac-
rophages) are generally associated with antitumor effects.
Chronic inflammation promotes cancer through multiple
mechanisms. Genomic instability and DNA damage, mediated
in part by reactive oxygen species (ROS), may cause genetic
and epigenetic mutations that initiate cell transformation and
cancer (Schetter et al., 2010). Inflammation also promotes tumor
progression by inducing tissue remodeling, supporting angio-
genesis, and providing growth factors (Schetter et al., 2010). In
all tumors, regardless of their etiopathogenesis, cancer-associ-
ated inflammation is present and maintains a tumor-promoting
milieu as well as an immunosuppressive environment, allowing
the tumor to escape immunity (Grivennikov et al., 2010).
Hematopoietic Response in Infection and Cancer
Hematopoietic stem cell (HSC) proliferation, the formation of
monocytes and granulocytes, extramedullary hematopoiesis,
and reactive increase of circulating neutrophils and inflammatory
monocytes are well-known responses to acute and chronic in-
fections. The regulation of bonemarrow (BM) HSCs is an integral
part of the first response to inflammation or stress. HSCs ex-
press innate receptors as well as chemokine and cytokine
receptors, and their mobilization, proliferation, and renewal is
regulated by cytokines released during infection (King and
Goodell, 2011). Leukocytosis, or an increase in white blood cells,
has also been frequently associated with cancer and attributed
to tumor cell production of colony-stimulating factors, which
induce HSC activation and differentiation (Ascensao et al.,
1987). Additionally, the contribution of myeloid cells to tumor
pathogenesis by promoting angiogenesis, tissue invasion, and
metastasis formation has been recently established (Shojaei
et al., 2007; Yan et al., 2010). Also, both the tumor microenviron-
ment and inflammation associated with infections endow some
mobilized myeloid cells with immunosuppressive activity (Gabri-
lovich et al., 2012).
HSCs are present in BM-specialized endosteal arteriolar
niches as quiescent or self-renewing cells (Kunisaki et al.,
2013). The large majority of HSCs are dormant and divide a
couple of times per year, whereas 5%–10% of HSCs are active,
divide once a month, and participate in their self-renewal while
generating a continuous output of all the hematopoietic lineages
in order to maintain homeostasis (Pietras et al., 2011). In296 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.response to injury observed in both infections and cancer, quies-
cent HSCs are detached from their endosteal niche and induced
into cell cycle and differentiation in vascular niches (Figure 1).
The factors regulating reactive hematopoiesis include early-
acting cytokines such as interleukin 3 (IL-3), IL-6, and Fms-like
tyrosine kinase 3 ligand as well as myeloid differentiating factors
such as granulocyte colony-stimulating factor (G-CSF), macro-
phage (M) CSF, and granulocyte (G)-M CSF (King and Goodell,
2011). Acute exposure to either type I interferons (IFNs) or
IFN-g triggers activation and cycling of HSCs and, together
with tumor necrosis factor (TNF), induces and skews the differ-
entiation of monocytic lineages (Baldridge et al., 2011; de Bruin
et al., 2012; Essers et al., 2009). However, chronic exposure to
these factors induces a loss of HSC repopulation ability, possibly
contributing to the hematopoietic defects observed in chronic in-
fections or cancer (Baldridge et al., 2011). Other factors include
neutrophil proteases that mobilize the HSCs from the endosteal
niches and ATP, which acts on purinergic receptors on HSCs to
induce cell cycling (Rossi et al., 2012). Ligands for the innate
immune Toll-like receptors (TLRs), such as endotoxin, DNA,
and endogenous ligands, directly activate HSCs or act indirectly
on mesenchimal and inflammatory cells (Boettcher et al., 2012;
Boiko and Borghesi, 2012).
Tumor cells can affect hematopoiesis by producing some of
these factors, such as IL-6, G-CSF, or GM-CSF, or activating
stromal cells to produce these cytokines. GM-CSF produced
by pancreatic cancer cells regulates myeloid inflammation and
is controlled by signaling through oncogenic Kras (Bayne et al.,
2012). Similarly, GM-CSF is induced by oncogenic Hras in skin
carcinogenesis in an IL-1-dependent manner (Salcedo et al.,
2013). Low levels of type I IFN present in tumors are important
for antitumor immunity and also centrally affect hematopoiesis
(Fuertes et al., 2013). Additionally, damaged tumor cells release
DAMPs involved in HSC mobilization. For example, mitochon-
drial damage releases DNA and formylpeptides, ligands for
TLR9, and the chemoattractant formyl peptide receptors,
respectively, and ATP is released by tumor cells damaged by
anthracyclines, a class of anticancer chemotherapeutics (Ma
et al., 2013a; Zhang et al., 2010).
The small number of HSCs normally present in circulation is
dramatically increased in response to inflammation, and their
homing to peripheral organs such as the liver, lung, and, in
experimental animals, spleen establishes foci of extra medullary
hematopoiesis. BM emargination of neutrophils depends on the
expression of ligands for the chemokine receptor CXCR2 (Ko¨hler
et al., 2011), whereas signaling through TLRs induces the secre-
tion of the chemokine ligand CCL2, which stimulates the egres-
sion of monocytes expressing the cognate chemokine receptor
CCR2 into the peripheral blood (Serbina and Pamer, 2006).
Then, CCR2+ inflammatory monocytes migrate in a mostly
CCR2-independent way to inflamed tissues or tumors, where
they can differentiate into distinct subsets of activated myeloid
cells sharing characteristics with macrophages and dendritic
cells (DCs) (Serbina and Pamer, 2006).
Myeloid Cells in Infection and Cancer
Myeloid-derived cells in cancer, infection, or other stress condi-
tions have been identified with different names, including
reactive neutrophils, inflammatory monocytes, macrophages,
Figure 1. Reactive Hematopoiesis in
Infection and Cancer
Factors produced by infected tissues or tumors
and their stroma induce the mobilization of HSCs
from endosteal arteriolar niches to vascular niches
and promote their proliferation and differentiation.
In response to chemotactic stimuli, HSCs, mono-
cytes, and neutrophils marginalize in the blood
circulation. HSCs reach organs such as liver and
spleen, where extramedullary hematopoiesis
occurs. Neutrophils and inflammatory monocytes
enter infected tissues and tumor stroma, where
monocytes differentiate into macrophage- or DC-
like cells. In infections, these inflammatorymyeloid
cell types, partly in response to MAMPs and IFN-g
secreted by NK cells, produce cytokines that favor
the generation of effector Th cells, often Th1, and
CTL. In tumors, various mediators present in
the microenvironment lead to the appearance of
myeloid cells with immunosuppressive activity and
favoring tumor growth and angiogenesis. In both
infections and cancer, the differentiation of the
myeloid cells in the inflamed tissue is modulated
by the presence of the gut microbiota. Myeloid
cells with immunosuppressive activities are also
observed in infections where they may contribute
to the resolution of inflammation and immunity,
whereas myeloid cells in the tumor can become
immunostimulating if properly stimulated and if the
activity of suppressive factors such as IL-10 is
inhibited.
Cell Host & Microbe
Reviewtumor-associated macrophages, DCs, immature myeloid cells,
myeloid suppressor cells, and others, often referring to cell
subsets with identical or indistinguishable surface phenotypes
(Table 1). The unified terminology of myeloid-derived suppressor
cells (MDSCs) has been proposed formyeloid cells present in the
BM, spleen, or tumor microenvironment and able to suppress
T cell responses (Gabrilovich et al., 2007). Reactivity with RB6-
8C5 antibody (anti-GR1) was initially used for the identification
of these cells. RB6-8C5 antibody recognizes the neutrophil-
specific Ly6G antigen but also cross-reacts with Ly6C
expressed on inflammatory monocytes. On the basis of Ly6C
and Ly6G expression, twomajor subsets of monocytic MDSC-M
and granulocytic MDSC-G, respectively, have been character-
ized (Gabrilovich et al., 2012).
Cells with the phenotypic characteristics of the so-called
MDSCs in the BM represent a differentiation stage of the granu-
locytic-monocytic lineage, and their increase in inflammation
probably reflects the reactive amplification of myelopoiesis
over erythropoiesis and lymphopoiesis. The augmented fre-
quency of these cells in the spleen could be due to the homing
of reactive myeloid cells or reflect extramedullary hematopoiesis
in this organ. The immunosuppressive activity of reactive
myeloid cells in spleen and tumors is not a property of subsets
of normal mature or immature myeloid cells (Gabrilovich and
Nagaraj, 2009) but instead appears to be endowed by the in-Cell Host & Microbe 1flamedmicroenvironment. Their immuno-
suppressive mechanisms have been
studied in both cancer and infection.
The major mechanism for MDSC-G is
ROS production with high expression of
the NOX2 NADPH oxidase that generates
ROS, whereas MDSC-M expresses nitricoxide (NO) synthase 2 that produces NO (Gabrilovich et al.,
2012). Other immunosuppressive mechanisms of tumor-associ-
ated myeloid cells are expression of arginases, surface galectin
9, and disintegrin andmetalloproteinase domain-containing pro-
tein 17, depletion of L-cysteine, and production of transforming
growth factor b, indoleamine-pyrrole 2,3-dioxygenase (IDO),
and IL-10 (Gabrilovich et al., 2012).
The immunosuppression mediated by reactive myeloid cells in
infection is critical for the resolution of acute inflammation and
exhaustion of immunity. In chronic lymphocyte choriomeningitis
virus infection, they accumulate and may play a role in its main-
tenance (Norris et al., 2013). Also, reactive myeloid cells may
contribute to immunodepression in HIV-infected patients (Qin
et al., 2013). During Toxoplasma gondii infection in mice, mono-
cyte-derived cells infiltrating the infected tissues are required for
the induction of a prototypic Th1 response by producing IL-12,
which induces IFN-g production and Th1 differentiation (Gold-
szmid et al., 2012). However, T. gondii acute infection also in-
duces IL-6 in BM stromal cells, reactive hematopoiesis, and
the expansion of regulatory myeloid cells that suppress the
lung-associated immune system through NO production (Chou
et al., 2012; Voisin et al., 2004). The cytokines regulating the
protective Th1 response to T. gondii, IL-12, and IFN-g endow
myeloid cells with NO-dependent immunosuppressive activity
(Voisin et al., 2004). Similarly, the use of IL-12 to elicit antitumor5, March 12, 2014 ª2014 Elsevier Inc. 297
Table 1. Myeloid Cells Associated with Infection and Cancer
Infection Site
Tumor
Microenvironment
Ly6Chi inflammatory
monocytes
PMN MDSC-Mo MDSC-G
CD45 + + + +
CD11b ++ ++ ++ ++
Gr-1 ++ +++ ++ +++
Ly6C +++ ++ +++ ++
Ly6G N.E. +++ N.E. +++
F4/80 + N.E. + N.E.
CD68 + N.E. + N.E.
CD115 ++ +/ ++ +/
CCR2 ++ + ++ +
Cx3CR1 + N.E. + N.E.
CXCR2 + ++ + ++
CXCR4 + + + +
CD124 + + + +
Ly6B (7/4) +++ ++ +++ ++
CD117 N.E. N.E. N.E. N.E.
CD11c +/ N.E. +/ N.E.
MHC II +/ +/ +/ N.E.
MHC I + + + +
CD49d ++ + ++ +
CD80 + + + +
RNS ++ + ++ +
ROS + ++ + ++
Induce strong Th1
pathogen killing
Immunosuppressive
promote tumor growth
The table shows the surface phenotype and ability to produce reactive
nitrogen and oxygen species (RNS and ROS) commonly reported for in-
flammatory monocytes and polymorphonuclear cells (PMNs) at infection
sites in comparison to tumor-associated MDSC-M and MDSC-G. In
infection, these myeloid cells are usually reported to induce a strong
Th1 response and pathogen killing, although, in some circumstances,
they may be immunosuppressive. Tumor-associated myeloid cells are
usually found to be immunosuppressive. N.E., not expressed.
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transient immunosuppression mediated by NO production from
reactive myeloid cells (Koblish et al., 1998). However, in polymi-
crobial sepsis induced in mice by cecal ligation and puncture
after an initial Th1-type inflammation, expansion of reactive
myeloid cells producing IL-10 induces the suppression of T cell
responses and Th2 polarization, possibly reflecting the life-
threatening immunosuppression following clinical sepsis (De-
lano et al., 2007). IL-10 production can be associated with Th2
response, but IL-10 induction in IFN-g-producing Th1 cells can
mediate the downregulation of the Th1 response in parasitic
and viral infections (Jankovic and Trinchieri, 2007). Thus, the
immunosuppressive mechanisms of tumor-associated myeloid
cells are characteristics of both classical (M1) and alternative
(M2) macrophage activation. During tumor progression, reactive
myeloid cells may mediate immunosuppression by either the
self-limiting mechanism of Th1 inflammation resolution (e.g.,
NO, ROS, and IL-10 production) or switching to a wound repair298 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.and angiogenic protumor Th2 inflammation with expression
of arginase, TGF-b, and IL-10. Repolarization of the tumor-
infiltrating myeloid cells by blocking IL-10 removes the
immunosuppressive brake and allows TLR ligands to induce
a tumor-eradicating Th1 inflammation and cytotoxic T cell
response (Guiducci et al., 2005).
Myeloid cell populations associated with infection and tumors
are heterogeneous and often described as immature cells. How-
ever, the immunosuppressive activity in these cells is not due to
their immaturity or the expansion of specialized subsets. Their
functions are very specialized and typical of differentiated cells
rather than immature cells. Phenotypic and gene expression
analysis of the reactive myeloid cells have shown differences
from their unactivated counterparts (monocytes, macrophages,
and neutrophils) but did not identify them as immature myeloid
cells. In infection models (e.g., T. gondii or Listeria monocyto-
genes infections), tissue-infiltrating monocytes differentiate into
macrophages and DC subsets, important for sustaining the
protective Th1 response, that are morphologically and pheno-
typically equivalent to the immunosuppressive myeloid cells
(Goldszmid et al., 2012). Differentiation of monocytes into Th1
promoting cells in T. gondii infection is controlled by natural killer
(NK)-cell-produced IFN-g (Goldszmid et al., 2012). IFN-g and
TNF not only induce reactive myelopoiesis but also shift the
myeloid differentiation toward monocytes and macrophages
and act even on differentiated neutrophils to induce morpholog-
ical and functional changes, including the appearance of imma-
ture nuclear morphology (de Bruin et al., 2012). Subsets of
neutrophils exist with different morphological appearance and
functions. Even terminally differentiated neutrophils can be
induced to proliferate changing their morphological appearance
and increasing their half-life (Beyrau et al., 2012). Thus, addi-
tional studies are needed for a full understanding of the nature
and mechanism of mobilization, differentiation, and activation
of immunosuppressive reactive myeloid cells.
Licensing of Immunity by the Commensal Microbiota
At epithelial surfaces, the microbiota modulates local inflamma-
tion and immunity. However, the commensal microbiota, partic-
ularly in the gut, also regulates systemic innate resistance and
adaptive immunity. The development of the immune system after
birth depends on exposure to the commensal microbiota. In
addition, themicrobiota modulates an inflammatory and immune
tone necessary for protection against infections. Some translo-
cation of microbes and their products through the skin and
mucosal barriers takes place in physiological conditions, and
this permeability increases during infections or inflammation. In
HIV patients, microbial translocation increases blood endotoxin
and microbial DNA and is considered to be a cause of the sys-
temic immune activation important for T cell depletion and
AIDS immunodeficiency (Qin et al., 2013).
The gut microbiota is required for the initiation of mouse lung
immunity against infection with respiratory viruses, increasing
the constitutive expression of the pro-IL-1b and pro-IL-18 genes
involved in proinflammatory responses as well as the ability to
produce and respond to IFN (Abt et al., 2012; Ichinohe et al.,
2011) (Figure 2). The commensal microbiota also poises inflam-
matory genes such as Ifnb1, Il6, and Tnf for transcription by
inducing epigenetic chromatin modifications (Ganal et al.,
Figure 2. Contribution of the Commensal
Microbiota to the Resistance to Infection
and Anticancer Therapy Effectiveness
The presence of the gut microbiota is essential for
resistance in the lungs to respiratory virus infection
and for the success of anticancer therapies in
subcutaneous tumors. Themicrobiota controls the
efficacy of CpG-oligonucleotide (ODN) therapy
combined with anti-IL-10R treatment by enabling
myeloid cells to produce TNF and the early geno-
toxic effect of oxaliplatin by enabling them to
release ROS. Gut transmucosal translocation of
bacteria induced by total-body irradiation (TBI)
or cyclophosphamide (CTX) treatment is required
for the anticancer effectiveness of adoptive T cell
transfer and for the induction of adaptive
immunity following CTX-induced immunogenic
cell death. The skin microbiota control skin im-
munity in a compartmentalizedway and is required
for an efficient immune response against L. major
infection.
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signaling is illustrated by the fact that TLR ligands, administered
locally in the lung or systemically, rescue anti-influenza immu-
nity in antibiotic-treated mice (Ichinohe et al., 2011). Although
the gut microbiota has systemic effects beyond intestinal
mucosal immunity, the control of skin immunity is compartmen-
talized, and resistance to cutaneous infection with Leishmania
major requires the presence of skin microbiota (Naik et al.,
2012).
The commensal microbiota also affects inflammation-depen-
dent carcinogenesis, tumor immunity, and response to therapy
(for a more detailed discussion about the role of microbiota in
colon cancer, see the review by Sears and Garrett [2014] in
this issue of Cell Host & Microbe). Mice unable to produce,
process, or respond to IL-18 display dysbiosis and have an
increased susceptibility to chemical colon and liver carcinogen-
esis that can be transferred to WT mice by cohousing (Elinav
et al., 2013; Salcedo et al., 2010). Colonic infection with Helico-
bacter hepaticus, a bacterium in the intestinal microbiota,
influences distant carcinogenesis by complex opposing mecha-
nisms: it enhances the number of small intestine and colon
polyps in the APCmin/+ mouse model of colon cancer and mam-
mary carcinoma in APCmin/+/Rag2/mice and increases chem-
ical and viral transgenic liver carcinogenesis (Fox et al., 2010),
but it also induces IL-10-producing T regulatory (T-reg) cells
that protect against intestinal and mammary carcinogenesis
(Rao et al., 1996). Furthermore, in the Atm/ mouse model of
ataxia-telangiectasia, natural or induced variation in intestinal
microbiota modifies lymphoma incidence (Yamamoto et al.,
2013). These profound effects of the gut microbiota on carcino-
genesis in distant organs are mediated by the modulation of the
TNF-dependent systemic inflammatory tone, oxidative stress,
and leukocyte or epithelial cell genotoxicity (Fox et al., 2010;
Westbrook et al., 2012; Yamamoto et al., 2013).Cell Host & Microbe 1In murine studies, the gut microbiota
has been shown to modulate myeloid-
derived cell functions in the tumor micro-
environment required for response to
immune and chemotherapy. Subcutane-
ous tumors of germ-free (GF) or antibi-otic-treated mice are impaired in their ability to respond to
CpG oligonucleotide immunotherapy and platinum chemo-
therapy (Iida et al., 2013). In these mice, tumor-infiltrating,
myeloid-derived cells have impaired production of various cyto-
kines, including TNF, following CpG oligonucleotide treatment
and show deficient ROS production and cytotoxicity following
chemotherapy. The presence of several Gram+ and Gram bac-
terial spp correlates with the response of tumor myeloid cells to
CpG oligonucleotides, whereas certain commensal Lactoba-
cillus spp. were found to decrease the response (Iida et al.,
2013). In addition to direct tumor cell cytotoxicity, some antineo-
plastic agents (e.g., cyclophosphamide [CTX]) induce an
adaptive antitumor immune response. In mice, CTX alters the
composition of the intestinal microbiota and induces mucositis,
or inflammation of the mucous membranes, associated with
translocation of Gram+ bacteria into draining lymph nodes that
enhance the generation of antitumor Th17 and memory Th1
immune responses (Viaud et al., 2013). Accordingly, GF or anti-
biotic-treated mice show relative resistance to CTX chemo-
therapy (Viaud et al., 2013). Thus, the activation of APCs and
induction of an antitumor immune response by immunogenic
death induced by chemotherapy is not only dependent on the
release of endogenous DAMPs by damaged tissue but is also
primed and/or enhanced by the contribution of MAMPs from
commensal bacteria. With a somewhat analogous mechanism,
total-body irradiation by inducing mucosal damage andmicrobi-
al translocation increase the efficacy of adoptively transferred
tumor-specific CD8+ T cells (Paulos et al., 2007).
Type I IFNs: More than Antiviral Cytokines
Type I IFNs are secreted polypeptides produced by virally in-
fected cells that induce a cell-intrinsic antiviral status in neigh-
boring cells that prevents the spread of the infection (Trinchieri,
2010). However, type I IFNs are induced by not only viral5, March 12, 2014 ª2014 Elsevier Inc. 299
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innate receptors activated by these ligands can trigger the pro-
duction of type I IFNs that play important roles in modulating
the differentiation and activated gene expression profile in in-
flammatory cells. Notably, TLR3, TLR7, TLR8, and TLR9 sense
endosomal nucleic acid, whereas, in the cytosol, the RIG-I-like
helicase receptors recognize RNA, whereas DNA is sensed by
stimulator of interferon gene directly or through a recently
defined family of DNA sensors (Bhat and Fitzgerald, 2013). In
addition to microbial nucleic acids, in tissues damaged by infec-
tion, tumor growth, or cytotoxic therapy, both nuclear and mito-
chondrial DNAmay be released and sensed by inflammatory and
other cells resulting in the production of IFN.
Type I IFNs also mediate several so-called ‘‘anticellular’’ activ-
ities, including the inhibition of cell proliferation, mobilization of
HSCs, inhibition, and skewing of hematopoietic cell differentia-
tion, antiangiogenesis, and immunomodulatory effects such as
activation of NK cell functions, modulation of DC activation,
migration, and antigen presentation functions, promotion of
T cell response and memory, and differentiation of plasma cells
(Trinchieri, 2010). Unlike their role in the innate response to acute
viral infections, type I IFN have contrasting and often deleterious
effects in the resistance to bacteria and play a role in the suscep-
tibility to bacterial superinfection complicating many viral infec-
tions (Trinchieri, 2010). Type I IFN immunosuppressive effects
also dominate and contribute to limiting the antiviral effect of
the IFN-g-producing CD4+ T cells and through NK cell activation
of the CD8+ cytotoxic T cells, thus contributing to chronic viral in-
fections (Odorizzi and Wherry, 2013). The immunosuppression
mediated by type I IFN in infection has been shown to be medi-
ated in part by the induction of IL-10 and the programmed death
1 (PD1) ligand PDL1, which initiates immune inhibitory signals
(Odorizzi and Wherry, 2013).
Type I IFN induced during infection, if maintained for an
extended time, may result in immunosuppression or autoim-
mune and hematologic pathology (Trinchieri, 2010). However,
constitutive physiological low-level IFN-b transcriptionally
controlled by c-Jun and NF-kB rather than interferon regulatory
factors is maintained by the commensal microbiota (Abt et al.,
2012; Ganal et al., 2012; Gough et al., 2012). Constitutive
IFN-b is required for maintaining hematopoietic homeostasis,
optimal proinflammatory cytokine production by myeloid cells,
and signaling in response to not only IFN but also unrelated
cytokines (Abt et al., 2012; Gough et al., 2012). In the absence
of tonic IFN-b signaling, animals are more susceptible to infec-
tion and cancer, have increased bone resorption and HSC
mobilization, and an IFN-g-dependent inflammatory pathology
(Gough et al., 2012).
The functions of type I IFN, including its immunomodulating,
antiangiogenic, antiproliferative, and proapoptotic effects, have
made it an obvious candidate for therapy in hematopoietic and
solid tumors, although its use has now been superseded by tar-
geted therapies (Trinchieri, 2010) due to severe toxicity that
includes autoimmune, inflammatory, hematological, and neuro-
logical side effects. High levels of type I IFNs, such as those
used in therapy, have a direct antitumor effect by regulating
cell proliferation, apoptosis, and autophagy. However, low levels
of type I IFNs are also present in tumors because of either basal
IFN-b production or active induction by DAMPs (Fuertes et al.,300 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.2013). Type I IFNs in the tumor microenvironment induce IL-10
from T-reg cells that control the protumor and proangiogenic
IL-17 (Stewart et al., 2013). It has been recently shown that
endogenous type I IFN acting on hematopoietic cells retards
the growth of mouse transplantable and carcinogen-induced
tumors, in particular through the activation of NK cells and
CD8a+ DCs as well as the inhibition of Th17 cells (Diamond
et al., 2011; Fuertes et al., 2013; Stewart et al., 2013). Low levels
of type I IFN are also required for the initial production of IL-12 by
CD11b+ DCs, whereas higher levels inhibit it (Gautier et al.,
2005). Although radiotherapy directly mediates tumor cell DNA
damage and cytotoxicity, ablative radiation of tumors induces
type I IFN production that acts on immune cells and is required
for treatment efficacy (Burnette et al., 2011).
Lymphoid Structures in Infected Tissues and Tumors
Although progressing tumors fail to induce protective immunity,
an ongoing chronic immune response to the tumor is often pre-
sent, and the extent and characteristics of tumor lymphocytic
infiltration has prognostic significance (Bindea et al., 2013).
Chronically inflamed tissues in infections, autoimmunity, and
cancer develop ectopic lymphoid follicles named tertiary
lymphoid organs (TLOs) (Neyt et al., 2012) (Figure 3). TLOs are
similar to secondary lymphoid organs but lack the capsule sur-
rounding the lymph nodes and resemble the organized lymphoid
tissue of the gut. They are composed of B and T cells in contin-
uous but separated anatomical structures, DCs, and macro-
phages; they also have stromal elements characteristic of
secondary lymphoid tissues (Link et al., 2011). As in secondary
lymphoid organs, lymphoid tissue inducer (LTi) cells, a subset
of innate lymphoid cells, are important for TLO formation. LTi
constitutively produce the cytokines lymphotoxin a (LTa) and
LTb that, along with LIGHT—another TNF family cytokine—are
sufficient to transform mesenchimal stromal cells into lymphoid
tissue organizer cells expressing CXCL13 or CCL19 and
CCL21 that recruit other cellular elements that form the TLOs
(van de Pavert et al., 2009). CD11b+ DCs are essential for TLO
maintenance via LTb production (GeurtsvanKessel et al.,
2009). However, IL-17- and IL-5-producing T cells can also act
on mesenchimal stromal cells, leading to TLO formation in the
absence of LTi cells (Rangel-Moreno et al., 2011).
TLOs function as an additional line of immune defense, allow-
ing local priming of naive T cells, and are necessary for effective
immune responses (Yu et al., 2004). By examining CD19 expres-
sion as a marker for B cells in different cancer samples in public
data sets (https://proteinatlas.org), we observed ectopic
lymphoid tissues in almost all cancer types except gliomas.
Other evidence has shown that the number of TLOs and pres-
ence of activated Th1-polarizing DCs in solid tumors positively
correlates with patient survival (Dieu-Nosjean et al., 2008;
Martinet et al., 2011). In mice, the induction of TLOs with LIGHT
resulted in the rejection of established tumors (Yu et al., 2004).
However, TLOs may also suppress antitumor immune response
and accelerate tumor growth (Shields et al., 2010). It has been
suggested that, following immunogenic cell death induced by
certain chemotherapy agents, antigen presentation may occur
in the tumor bed independently of draining lymph nodes or
TLOs (Ma et al., 2013a). Additional in vivo imaging studies are
required to directly identify the relationship between cellular
Figure 3. Tertiary Lymphoid Organs in Infection and Cancer
(A) In chronic infections, such as in the lung of influenza-virus-infected mice shown here, TLOs are present and characterized by anatomically contiguous but
separated T (CD4+ or CD8+) and B cell areas (B220+) and the presence of conventional (CD11C+) or follicular DCs (FDCs), suggesting localized sites of T and B cell
responses (reproduced with permission from GeurtsvanKessel et al., 2009).
(B–D) TLOs are often present in tumors as visualized by the B cell marker CD19 (from http://www.proteinatlas.org).
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be considered a compensatory mechanism for chronically in-
flamed tissues that have decreased lymphatic drainage and
APC migration (Thaunat et al., 2006).
NegativeRegulation of Immunity in Infection andCancer
The immune response is selectively controlled in different tissues
to achieve a balance between an effective response andminimal
collateral damage until immune safe checkpoints are initiated
(Matzinger and Kamala, 2011). The level of protection is particu-
larly robust in organs with limited spontaneous regeneration
(e.g., the central nervous system) (Iliff et al., 2012), whereas, in
other tissues, a more regulatory type of control is established.
Many vital organs express high levels of TGF-b (and its activating
enzyme, MMP9) that directly suppress T and NK cell responses
and induce T-reg cells. In the intestine, the cohabitation with
commensal bacteria is facilitated by the presence of IL-10-
producing T-reg cells that are induced by a subset of CD103 ex-
pressing DCs primed by the mucus-forming protein mucin 2
(MUC2) (Shan et al., 2013) and activated by environmental
cues, such as bacterial short-chain fatty acids, which act via
free fatty acid receptor 2 or the TLR2 agonist polysaccharide A
found on the bacterial surface (Round et al., 2011; Smith et al.,
2013). Many tumors hijack the mechanisms of tolerance induc-
tion, for instance, by expressing high levels of TGF-b (Meul-
meester and Ten Dijke, 2011) and IDO (Wainwright et al.,
2012), or mimic the intestinal tolerant microenvironment by
the presence of activated IL-10-producing T-reg cells (Stewartet al., 2013) (Figure 4). Tumor-associated T-reg cells have the
opposite effects on tumor progression by regulating proangio-
genic Th17 cells but also the antitumor T cell response; the tran-
sient depletion of T-reg cells slow tumor progression and
improve the efficacy of radiation therapy (Bos et al., 2013;
Stewart et al., 2013).
During acute infection, the number of antigen-specific T cells
rapidly increases, peaking around days 7–10. Once the path-
ogen is cleared, the majority of T cells undergo apoptosis, leav-
ing a small number of memory cells able to rapidly respond to
secondary challenge. In chronic infection, the immune response
is suppressed by variousmechanisms to prevent tissue damage,
and T cells acquire an exhausted phenotype characterized by
the loss of effector molecules (IFN-g, TNF, granzymes, and
perforin) and the upregulation of inhibitory molecules, such
as cytotoxic T lymphocyte-associated antigen 4 (CTLA4 or
CD152), PD-1 (or CD279), lymphocyte-activation gene 3 (LAG3
or CD223), T cell immunoglobulin and mucin protein 3 (TIM-3),
adenosine receptor, killer-cell immunoglobulin-like receptors,
and several others. Although tumors rarely induce an acute
immune response, T cells in the tumor environment have an ex-
hausted phenotype and are restrained by both tissue-intrinsic
tolerogenic mechanisms as well as mechanisms responsible
for the contraction of the immune response to infections (Crespo
et al., 2013). T cell exhaustion is reversible by the removal of
inhibitory signals. CTLA4 competes with CD28 for binding to
CD80/CD86 on DCs and is an important negative regulator
in infection and cancer (Kaufmann and Walker, 2009; LeachCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 301
Figure 4. Main Immune Checkpoints
Negatively Regulating the Immune
Response in Infection and Cancer
T cells in the tumor environment have an ex-
hausted phenotype, and their proliferation and
activation are restrained by both tissue-intrinsic
tolerogenic mechanisms that limit excessive in-
flammatory and immune response to infection as
well as by the mechanisms responsible for the
contraction of the immune response to infection.
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Reviewet al., 1996). CTLA4 also scavenges CD80 from the surface of
DCs and induces IDO production, mechanisms that may explain
how CTLA4-expressing T-reg cells inhibit T cell responses (Fal-
larino et al., 2005; Wing et al., 2008). PD-1 has T-cell-inhibitory
properties in chronic infections and cancer (Barber et al., 2006;
Zha et al., 2004). LAG-3 and TIM-3 are also highly expressed
on the surface of exhausted T cells (Anderson, 2012; Blackburn
et al., 2009; Norde et al., 2012).
T cells also directly sense the environment and modify the
strength of TCR signaling; e.g., by assessing nutrient availability
and oxygen levels. Hypoxia-inducible factor I activated in the
hypoxic conditions observed in chronically inflamed tissues
and tumors determines the activity of cytotoxic CD8 T cells by
inducing increased production of effector molecules (e.g., per-
forin and granzymes) as well as increasing the levels of inhibitory
molecules, such as CTLA4 and LAG3 (Doedens et al., 2013).
Nutrient availability, due to low blood supply or altered cell meta-
bolism, mostly sensed by mammalian target of rapamycin
(mTOR) and general control nonrepressed 2, also affects T cell
responses (McGaha et al., 2012). Myeloid, stromal, and tumor
cells similarly modulate mTOR activity and strength of TCR
signaling in T cells by producing enzymes that deplete essential
amino acids such as IDO, which regulates tryptophan, in imme-
diate T cell environment.
Conclusions
Unlike vaccines against pathogens, cancer vaccines have so far
obtained only limited clinical success, which is most likely due to
the persistency of an immunosuppressive tumor microenviron-
ment. As discussed above, the immune environment created
by the tumor recapitulates that present in chronic infections in302 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.which homeostatic mechanisms aimed
at preventing excessive inflammation
and tissue damage establish immunolog-
ical checkpoints that prevent an effective
immune response able to completely
eliminate the pathogens or destroy the
tumor. Thus, immunoinhibitory mecha-
nisms responsible for chronic infection,
such as the local production of IL-10,
type I IFN, IDO, and TGF-b, and ligands
for inhibitory coreceptors are also present
in the tumor microenvironment (Diamond
et al., 2011; Guiducci et al., 2005; Odorizzi
and Wherry, 2013; Pardoll, 2012; Stewart
et al., 2013). Therefore, it is not surprising
that the effectiveness of procedures sim-
ply directed to induce a new response totumor antigens or enhance the natural response is prevented
by the same mechanisms that limit the ability of immunosurveil-
lance to prevent the growth of the tumors.
Many of the mechanisms regulating the immune responses to
infections and cancer discussed in this review are derived from
studies in experimental animals. Although it is important to avoid
an automatic extrapolation from mouse studies to humans due
to the differences in the immune systems between the two spe-
cies and the limitations of the experimental models of cancer, the
recent success in cancer immunotherapy indicates that the in-
formation from mouse studies can be useful for the design of
clinical approaches. Thus, in both chronic infectious disease
and tumor immunotherapy, much effort has been devoted to
developing strategies for reversing immunosuppression; e.g.,
better adjuvants or blockers of immunosuppressive factors
such as TFG-b, IDO, or IL-10. The most promising advances
have been obtained with antibodies that block coinhibitory
molecules. The monoclonal antibody to CTLA4 (ipilimumab),
approved for use in patients with metastatic melanoma, in-
creases patients’ survival most likely by amplifying the endoge-
nous antitumor T cell response. Antibodies against PD1 receptor
or its ligand PD-L1 induce significant clinical responses in
patients with melanoma or other solid tumors, such as lung can-
cer (Pardoll, 2012). The effectiveness of these new drugs sug-
gests that, in a proportion of patients, the endogenous immune
response to cancer is sufficient to induce tumor regression.
Thus, there is an optimistic expectation that the combination of
immunocheckpoint inhibitors with therapies such as cancer vac-
cines or certain chemotherapies that amplify the antitumor
immune response might offer better chances for therapeutic
success. Recent studies have also identified the existence of
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Reviewmemory T cells with stem-cell-like properties in viral infections
and tumors that maintain the ability to develop in potent effector
T cells; the expansion of these cells or reprogramming terminally
differentiated tumor-infiltrating lymphocytes to confer stem-cell-
like properties might be used to augment immunotherapies
against cancer (Gattinoni et al., 2012). The promise of these
new therapeutic approaches proves the usefulness of compara-
tive studies in infectious and cancer immunity for a better under-
standing of their basic mechanisms and translational application
for the development of new therapies.REFERENCES
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